The AID trial evaluated the addition of abatacept to standard therapy in 10 participants aged seven to 17 years with refractory juvenile dermatomyositis in an open-label setting in the United States. The results showed:
- a significant improvement in most of the evaluation criteria (muscle testing, skin disease activity, fatigue…) in nine participants after 24 weeks of abatacept ;
- a favorable evolution of the mean score of muscle edema on magnetic resonance imaging;
- a downward trend in the interferon score for six participants;
- a cortisone-sparing effect, with a reduction from 16.7 mg/d to 10.2 mg/d of corticosteroids on average.
In contrast, the international NCT02971683 trial, which included three investigative sites in France (Brest, Lille and Strasbourg), was terminated prematurely because the selected efficacy criteria were not met. It enrolled 149 adults with refractory dermatomyositis, polymyositis, autoimmune necrotizing myopathy or overlap syndrome.
